Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy

Breast Cancer Research and Treatment

Volumn 118, Issue 1, 2009, Pages 45-56

  Specht, Katja ^a   Harbeck, Nadia ^b   Smida, Jan ^c   Annecke, Katja ^b   Reich, Ulrike ^c   Naehrig, Joerg ^a   Langer, Rupert ^a   Mages, Joerg ^d   Busch, Raymonde ^b   Kruse, Elisabeth ^e   Klein Hitpass, Ludger ^e   Schmitt, Manfred ^b   Kiechle, Marion ^b   Hoefler, Heinz ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adjuvant CMF Chemotherapy; Breast Cancer; Microarray; Prediction; Quantitative RT PCR; Recurrence

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; DECISION MAKING; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOKINE CXCL9; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEIN ALPHA SUBUNIT, GI2; HISTONES; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MASTECTOMY; METHOTREXATE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECURRENCE; RNA, MESSENGER; RNA, NEOPLASM;

EID: 70349898988     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0207-y     Document Type: Article

References (36)

1. P Eifel JA Axelson J Costa J Crowley WJ Curran Jr A Deshler, et al. 2001 National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000 J Natl Cancer Inst 93 979 989 10.1093/jnci/93.13.979 10.1093/jnci/93.13.979 1:STN:280: DC%2BD3MzpvFamtA%3D%3D 11438563
2. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 1 15
3. Early Breast Cancer Trialists' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 942 10.1016/S0140-6736(98)03301-7 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
4. G Bonadonna P Valagussa A Moliterni M Zambetti C Brambilla 1995 Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 901 906 10.1056/NEJM199504063321401 10.1056/NEJM199504063321401 1:STN:280: DyaK2M7otlSqsg%3D%3D 7877646
5. MN Levine VH Bramwell KI Pritchard BD Norris LE Shepherd H Abu-Zahra, et al. 1998 Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 16 2651 2658 1:CAS:528:DyaK1cXlsFCguro%3D 9704715
6. A Goldhirsch JH Glick RD Gelber AS Coates B Thurlimann HJ Senn 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569 1583 10.1093/annonc/mdi326 10.1093/annonc/mdi326 1:STN:280:DC%2BD2MvpvFKhsA%3D%3D 16148022 (Pubitemid 41511089)
7. KI Pritchard LE Shepherd FP O'Malley IL Andrulis D Tu VH Bramwell, et al. 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2103 2111 10.1056/NEJMoa054504 10.1056/NEJMoa054504 1:CAS:528:DC%2BD28XkslCku7s%3D 16707747 (Pubitemid 43736610)
8. MS Askmalm J Carstensen B Nordenskjold B Olsson LE Rutqvist L Skoog, et al. 2004 Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients Acta Oncol 43 235 244 10.1080/02841860410029474 10.1080/02841860410029474 1:CAS:528: DC%2BD2cXlslSlur8%3D 15244246 (Pubitemid 38757044)
9. J Andersson L Larsson S Klaar L Holmberg J Nilsson M Inganas, et al. 2005 Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF Ann Oncol 16 743 748 10.1093/annonc/mdi150 10.1093/annonc/mdi150 1:STN:280:DC%2BD2M3gvVamsw%3D%3D 15802278 (Pubitemid 40767094)
10. S Paik S Shak G Tang C Kim J Baker M Cronin, et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817 2826 10.1056/NEJMoa041588 10.1056/NEJMoa041588 1:CAS:528:DC%2BD2MXhslymsw%3D%3D 15591335 (Pubitemid 40051905)
11. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 10.1111/j.1365-2559. 1991.tb00229.x 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280: DyaK38%2FpvVSltw%3D%3D 1757079
12. TR Golub DK Slonim P Tamayo C Huard M Gaasenbeek JP Mesirov, et al. 1999 Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286 531 537 10.1126/science.286.5439.531 10.1126/science.286.5439.531 1:CAS:528:DyaK1MXmvVOhu7g%3D 10521349
13. P Tamayo D Slonim J Mesirov Q Zhu S Kitareewan E Dmitrovsky, et al. 1999 Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation Proc Natl Acad Sci USA 96 2907 2912 10.1073/pnas.96.6.2907 10.1073/pnas.96.6.2907 1:CAS:528:DyaK1MXhvFyks7k%3D 10077610 (Pubitemid 29148817)
14. LJ van't Veer H Dai MJ van de Vijver YD He AA Hart M Mao, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 10.1038/415530a 10.1038/415530a (Pubitemid 34130608)
15. MJ van de Vijver YD He LJ van't Veer H Dai AA Hart DW Voskuil, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 1999 2009 10.1056/NEJMoa021967 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
16. D Hwang WA Schmitt G Stephanopoulos 2002 Determination of minimum sample size and discriminatory expression patterns in microarray data Bioinformatics 18 1184 119317 10.1093/bioinformatics/18.9.1184 1:CAS:528:DC%2BD38XmvVCqsLc%3D 12217910
17. S Mukherjee P Tamayo S Rogers R Rifkin A Engle C Campbell, et al. 2003 Estimating dataset size requirements for classifying DNA microarray data J Comput Biol 10 119 142 10.1089/106652703321825928 1:CAS:528:DC%2BD3sXjvFClsb8%3D 12804087 (Pubitemid 36623535)
18. M Ayers WF Symmans J Stec AI Damokosh E Clark K Hess, et al. 2004 Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 22 2284 2293 10.1200/JCO.2004.05.166 10.1200/JCO.2004.05.166 1:CAS:528:DC%2BD2cXpsVWltLo%3D 15136595 (Pubitemid 41115384)
19. S Datta S Datta 2003 Comparisons and validation of statistical clustering techniques for microarray gene expression data Bioinformatics 19 459 466 10.1093/bioinformatics/btg025 10.1093/bioinformatics/btg025 1:CAS:528: DC%2BD3sXit1yns70%3D 12611800 (Pubitemid 36336511)
20. SG Hilsenbeck WE Friedrichs R Schiff P O'Connell RK Hansen CK Osborne, et al. 1999 Statistical analysis of array expression data as applied to the problem of tamoxifen resistance J Natl Cancer Inst 91 453 459 10.1093/jnci/91.5.453 10.1093/jnci/91.5.453 1:STN:280:DyaK1M7mvVCqsQ%3D%3D 10070945
21. E Huang SH Cheng H Dressman J Pittman MH Tsou CF Horng, et al. 2003 Gene expression predictors of breast cancer outcomes Lancet 361 1590 1596 10.1016/S0140-6736(03)13308-9 10.1016/S0140-6736(03)13308-9 1:CAS:528: DC%2BD3sXjs1Wltbo%3D 12747878 (Pubitemid 36578995)
22. C Sotiriou SY Neo LM McShane EL Korn PM Long A Jazaeri, et al. 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 10393 10398 10.1073/pnas.1732912100 10.1073/pnas.1732912100 1:CAS:528:DC%2BD3sXntFynsrk%3D 12917485 (Pubitemid 37071889)
23. C Sgadari JM Farber AL Angiolillo F Liao J Teruya-Feldstein PR Burd, et al. 1997 Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo Blood 89 2635 2643 1:CAS:528:DyaK2sXisFCju7k%3D 9108380
24. R Dorsey N Kundu Q Yang CS Tannenbaum H Sun TA Hamilton, et al. 2002 Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma Cancer Res 62 2606 2610 1:CAS:528:DC%2BD38XjtlGrtrg%3D 11980656
25. T Kondo F Ito H Nakazawa S Horita Y Osaka H Toma 2004 High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma J Urol 171 2171 2175 10.1097/01.ju.0000127726.25609.87 10.1097/01.ju.0000127726.25609. 87 1:CAS:528:DC%2BD2cXkvVWhsr8%3D 15126779 (Pubitemid 38625428)
26. N Mochizuki Y Ohba E Kiyokawa T Kurata T Murakami T Ozaki, et al. 1999 Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i) Nature 400 891 894 10.1038/23738 10.1038/23738 1:CAS:528: DyaK1MXlslGrs7s%3D 10476970 (Pubitemid 29406727)
27. C Pucharcos X Estivill S de la Luna 2000 Intersectin 2, a new multimodular protein involved in clathrin-mediated endocytosis FEBS Lett 478 43 51 10.1016/S0014-5793(00)01793-2 10.1016/S0014-5793(00)01793-2 1:CAS:528:DC%2BD3cXltVGrsbw%3D 10922467 (Pubitemid 30462256)
28. DA Schafer 2002 Coupling actin dynamics and membrane dynamics during endocytosis Curr Opin Cell Biol 14 76 81 10.1016/S0955-0674(01)00297-6 10.1016/S0955-0674(01)00297-6 1:CAS:528:DC%2BD38XktFGrsw%3D%3D 11792548 (Pubitemid 34131660)
29. E Niméus-Malmström C Ritz P Edén A Johnsson M Ohlsson C Strand, et al. 2006 Gene expression profiles and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy Eur J Cancer 42 2729 2737 10.1016/j.ejca.2006.06.031 10.1016/j.ejca.2006.06.031 17023159 (Pubitemid 44584675)
30. S Paik G Tang S Shak C Kim J Baker W Kim, et al. 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726 3734 10.1200/JCO.2005.04.7985 10.1200/JCO.2005.04.7985 1:CAS:528:DC%2BD28XpsVaqsrs%3D 16720680 (Pubitemid 46622311)
31. M Martin A Villar A Sole-Calvo R Gonzalez B Massuti J Lizon, et al. 2003 Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 833 842 10.1093/annonc/mdg260 10.1093/annonc/mdg260 1:STN:280:DC%2BD3s3mvFGnsw%3D%3D 12796019 (Pubitemid 36827198)
32. G Bonadonna M Zambetti A Moliterni L Gianni P Valagussa 2004 Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer J Clin Oncol 22 1614 1620 10.1200/JCO.2004.07.190 10.1200/JCO.2004.07.190 1:CAS:528: DC%2BD2cXpsVWmu7o%3D 15117983 (Pubitemid 41079799)
33. JC Chang EC Wooten A Tsimelzon SG Hilsenbeck MC Gutierrez R Elledge, et al. 2003 Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 362 369 10.1016/S0140-6736(03)14023-8 10.1016/S0140-6736(03)14023-8 1:CAS:528: DC%2BD3sXlvFGnsLo%3D 12907009 (Pubitemid 36957839)
34. O Thuerigen A Schneeweiss G Toedt P Warnat M Hahn H Kramer, et al. 2006 Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer J Clin Oncol 24 1839 1845 10.1200/JCO.2005.04.7019 10.1200/JCO.2005.04.7019 1:CAS:528: DC%2BD28XkvVajtL4%3D 16622258 (Pubitemid 46638981)
35. A Rody T Karn R Gätje K Kourtis G Minckwitz S Loibl, et al. 2006 Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures Zentralbl Gynakol 128 76 81 10.1055/s-2006-921508 10.1055/s-2006-921508 1:CAS:528:DC%2BD28Xlt1Sru7k%3D 16673249
36. A Rody T Karn C Solbach R Gaetje M Munnes S Kissler, et al. 2007 The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial Breast 16 235 240 10.1016/j.breast.2007.02.006 10.1016/j.breast.2007.02.006 1:STN:280: DC%2BD2szis12gsw%3D%3D 17449250 (Pubitemid 46796861)